Siltuximab
- Generic Name
- Siltuximab
- Brand Names
- Sylvant
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 541502-14-1
- Unique Ingredient Identifier
- T4H8FMA7IM
- Background
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of...
- Indication
Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.
- Associated Conditions
- Castleman Disease
- Associated Therapies
- -
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 215
- Registration Number
- NCT06679829
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Paolo Caimi, MD
- Target Recruit Count
- 20
- Registration Number
- NCT06447376
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Jack Khouri
- Target Recruit Count
- 20
- Registration Number
- NCT06352866
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, Cleveland, Ohio, United States
Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT05697510
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05684692
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 6
- Registration Number
- NCT05316116
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 30
- Registration Number
- NCT04975555
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- EusaPharma (UK) Limited
- Target Recruit Count
- 22
- Registration Number
- NCT04838860
- Locations
- 🇺🇸
Edward W. Sparrow Hospital, Lansing, Michigan, United States
SILtuximab in Viral ARds (SILVAR) Study
- Conditions
- Interventions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- EusaPharma (UK) Limited
- Target Recruit Count
- 555
- Registration Number
- NCT04616586
- Locations
- 🇺🇸
Atrium Health, Charlotte, North Carolina, United States
🇺🇸Sparrow Clinical Research Institute, Lansing, Michigan, United States
Treatment of COVID-19 Patients With Anti-interleukin Drugs
- Conditions
- Interventions
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 342
- Registration Number
- NCT04330638
- Locations
- 🇧🇪
University Hospital Antwerp, Edegem, Belgium
🇧🇪Ziekenhuis Oost-Limurg, Genk, Belgium
🇧🇪AZ Delta, Roeselare, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.